SAN 8.27 Banco Santander $SAN Hit a 52 week low of 8.10 Closing the day 11/07/14 at 8.27 -0.10 -1.19% With a day low of 8.10 and a total volume of 10,741,630.
SAN Recent Posts: http://investorshangout.com/Banco-Santander-S...SAN-52719/
SAN Banco Santander Recent Headline News
Providence drops suit vs. Santander over lending
By JENNIFER McDERMOTT - AP - Fri Nov 07, 12:42PM CST
PROVIDENCE, R.I. (AP) — Santander Bank has agreed to give $1.3 million in grants to support low- and moderate-income neighborhoods in Providence to resolve a lawsuit filed by the city.
SAN: 8.27 (-0.10), SANW: 3.08 (+0.01)
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Business Wire - Tue Nov 04, 5:00AM CST
Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme's investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
Banco Santander Brasil (BSBR) Stock Continues to Sink After Share Buyout
at The Street - Mon Nov 03, 10:03AM CST
Banco Santander Brasil (BSBR) stock continues to tumble after its parent company raised its stake in the Brazilian unit to 88.3% last Friday.
SAN: 8.27 (-0.10), BSBR: 5.53 (-0.03)
Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older
PR Newswire - Mon Nov 03, 7:30AM CST
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone® High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza ("the flu"
compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age and older.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
Conference Participation, Dividend, Upcoming Annual Meeting, Training Program, and Promotional Event - Research Reports on Santander Brasil, Goldman Sachs, Visa, Banco Santander and American Express
PR Newswire - Thu Oct 30, 7:30AM CDT
Today, Analysts Review released its research reports regarding Banco Santander Brasil SA (NYSE: BSBR), The Goldman Sachs Group Inc. (NYSE: GS), Visa Inc. (NYSE: V), Banco Santander, S.A. (NYSE: SAN) and American Express Company (NYSE: AXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7556-100free.
SAN: 8.27 (-0.10), V: 252.43 (+2.34), GS: 190.71 (-0.29), AXP: 92.26 (+0.68), BSBR: 5.53 (-0.03)
Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
PR Newswire - Tue Oct 28, 7:34AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors
PR Newswire - Tue Oct 28, 5:00AM CDT
The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of an ambitious new international partnership. Called the GPCR Consortium, this non-profit initiative brings together major pharmaceutical companies and leading research institutes from three continents to advance GPCR research for drug development. The human body is controlled by 826 GPCRs, which are involved in a wide variety of human physiology and are implicated in many diseases. As a drug target, GPCRs are highly valuable but mechanistically poorly understood and with limited structural information that could greatly aid in finding new drug candidates.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
Sanofi Q3 2014 Results - Interview with Jérôme Contamine
PR Newswire - Tue Oct 28, 2:00AM CDT
Sanofi, a global and diversified healthcare leader, reports results for the third-quarter of 2014. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on results and full year guidance.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
SmarTrend Watching for Potential Rebound in Shares of Banco Santander After 2.58% Loss
Comtex SmarTrend(R) - Mon Oct 27, 4:08PM CDT
Banco Santander (NYSE:SAN) traded in a range yesterday that spanned from a low of $8.51 to a high of $8.72. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $8.67 on volume of 38.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SAN: 8.27 (-0.10)
80% ECB Banks Pass Stress Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:55AM CDT
European banks emerged as healthier. Of 123 banks that were part of the stress test, only 24 failed to meet the minimum common equity ratio (CET1) level of 5.5%.
BCS: 14.91 (-0.10), SAN: 8.27 (-0.10), HSBC: 50.09 (-0.27), DB: 30.24 (-0.38), NBG: 2.34 (-0.09), RBS: 11.90 (-0.16), LYG: 4.82 (unch)
Review on Diversified Banks Stocks - US Bancorp, Banco Santander Brasil, Banco Santander, National Bank of Greece, and Comerica
PR Newswire - Fri Oct 24, 8:10AM CDT
Investor-Edge has initiated coverage on the following equities: US Bancorp (NYSE: USB), Banco Santander Brasil S.A. (NYSE: BSBR), Banco Santander S.A. (NYSE: SAN), National Bank of Greece S.A. (NYSE: NBG), and Comerica Inc. (NYSE: CMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 23, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,677.90, up 1.32% and the NASDAQ Composite closed at 4,452.79, up 1.60%. The S&P 500 finished the session 1.23% higher at 1,950.82. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Financials Sector Index ended the day at 308.34, up 0.98%, with the index advancing 4.62% on YTD basis. Register for your complimentary reports on these five stocks at:
SAN: 8.27 (-0.10), USB: 43.81 (-0.11), NBG: 2.34 (-0.09), CMA: 48.40 (-0.50), BSBR: 5.53 (-0.03)
Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
PR Newswire - Wed Oct 22, 9:54AM CDT
Santander Holdings USA, Inc. (SHUSA), parent company of Santander Bank, N.A., announced today that its Board of Directors declared a dividend on SHUSA's Preferred Stock. A dividend payment of $0.45625 per depositary share is payable on November 17, 2014 to holders of record on November 1, 2014 for SHUSA's Series C Non-Cumulative Perpetual Preferred Stock (NYSE: SOVPRC).
SAN: 8.27 (-0.10)
Results from Two Phase III Studies Added to U.S. Label of Genzyme's Aubagio
Business Wire - Mon Oct 20, 9:35AM CDT
Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio(R) (teriflunomide) in the product's U.S. label.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
Business Wire - Mon Oct 20, 7:01AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies' investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB(1), has been accepted for review by the U.S. Food and Drug Administration (FDA). If approved, it would be the first pediatric combination vaccine in the United States designed to help protect against six important diseases - diphtheria, tetanus, pertussis (whooping cough), polio (poliovirus types 1, 2, and 3), invasive disease caused by Haemophilus influenzae type b (Hib), and hepatitis B.
SAN: 8.27 (-0.10), MRK: 59.34 (+0.08), SNY: 45.69 (-0.17)
Regeneron Pharmaceuticals begins Phase 3 clinical study of dupilumab in adults patients with moderate-to-severe atopic dermatitis
M2 - Mon Oct 20, 6:53AM CDT
Biopharmaceutical company Regeneron Pharmaceuticals (NasdaqGS :REGN) said on Monday that it has dosed the first patients in a Phase 3 clinical study of dupilumab in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications in partnership with Sanofi (EURONEXT:SAN)(NYSE:SNY) .
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
PR Newswire - Mon Oct 20, 6:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Homeownership Programs, New Apps for Mortgage and Real Estate Professionals, Dividend, and Market Activity - Research Reports on Radian, Banco Santander, BioMed Realty, Chimera and Genworth
PR Newswire - Fri Oct 17, 7:35AM CDT
Today, Analysts Review released its research reports regarding Radian Group Inc. (NYSE: RDN), Banco Santander, S.A. (NYSE: SAN), BioMed Realty Trust Inc. (NYSE: BMR), Chimera Investment Corporation (NYSE: CIM) and Genworth Financial, Inc. (NYSE: GNW). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7255-100free.
SAN: 8.27 (-0.10), BMR: 21.44 (+0.02), RDN: 16.48 (+0.09), CIM: 3.14 (+0.01), GNW: 8.41 (-0.25)
Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
GlobeNewswire - Thu Oct 16, 7:19AM CDT
Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that it has entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN) and (NYSE:SNY).
IMDZ: 30.06 (-0.03), SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
New Survey Finds Differences In Attitudes About Diabetes Based On Age
PR Newswire - Wed Oct 15, 7:00AM CDT
Sanofi US announced today the findings of a new survey that reveals striking differences in opinion among various age groups about diabetes and available treatment options. In particular, the generation known as "millennials" (those aged 18 to 34) shows an uneasy mix of fear and ability to handle managing their diabetes, which is being diagnosed at a rate of 1.7 million new cases every year1.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
1 Bank Stock to Avoid at All Costs
Motley Fool Staff - Motley Fool - Mon Oct 13, 11:35AM CDT
There are certainly some bargains to be had in the banking sector, with many companies trading at historically low valuations and growing their operations very rapidly. However, some stocks might appear to be better investments than they actually...
SAN: 8.27 (-0.10), NYCB: 15.91 (+0.07), BAC: 17.36 (unch), FBP: 5.25 (unch), MCO: 98.95 (-0.04)
SAN Recent Posts: http://investorshangout.com/Banco-Santander-S...SAN-52719/
SAN Banco Santander Recent Headline News
Providence drops suit vs. Santander over lending
By JENNIFER McDERMOTT - AP - Fri Nov 07, 12:42PM CST
PROVIDENCE, R.I. (AP) — Santander Bank has agreed to give $1.3 million in grants to support low- and moderate-income neighborhoods in Providence to resolve a lawsuit filed by the city.
SAN: 8.27 (-0.10), SANW: 3.08 (+0.01)
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
Business Wire - Tue Nov 04, 5:00AM CST
Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme's investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
Banco Santander Brasil (BSBR) Stock Continues to Sink After Share Buyout
at The Street - Mon Nov 03, 10:03AM CST
Banco Santander Brasil (BSBR) stock continues to tumble after its parent company raised its stake in the Brazilian unit to 88.3% last Friday.
SAN: 8.27 (-0.10), BSBR: 5.53 (-0.03)
Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older
PR Newswire - Mon Nov 03, 7:30AM CST
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone® High-Dose (Influenza Vaccine) to include efficacy data in the Prescribing Information. These data demonstrate that Fluzone High-Dose vaccine provided improved protection against influenza ("the flu"
compared to standard-dose Fluzone vaccine (trivalent intramuscular formulation) in adults 65 years of age and older. SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
Conference Participation, Dividend, Upcoming Annual Meeting, Training Program, and Promotional Event - Research Reports on Santander Brasil, Goldman Sachs, Visa, Banco Santander and American Express
PR Newswire - Thu Oct 30, 7:30AM CDT
Today, Analysts Review released its research reports regarding Banco Santander Brasil SA (NYSE: BSBR), The Goldman Sachs Group Inc. (NYSE: GS), Visa Inc. (NYSE: V), Banco Santander, S.A. (NYSE: SAN) and American Express Company (NYSE: AXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7556-100free.
SAN: 8.27 (-0.10), V: 252.43 (+2.34), GS: 190.71 (-0.29), AXP: 92.26 (+0.68), BSBR: 5.53 (-0.03)
Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
PR Newswire - Tue Oct 28, 7:34AM CDT
Sanofi (NYSE: SNY; EURONEXT: SAN)
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors
PR Newswire - Tue Oct 28, 5:00AM CDT
The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of an ambitious new international partnership. Called the GPCR Consortium, this non-profit initiative brings together major pharmaceutical companies and leading research institutes from three continents to advance GPCR research for drug development. The human body is controlled by 826 GPCRs, which are involved in a wide variety of human physiology and are implicated in many diseases. As a drug target, GPCRs are highly valuable but mechanistically poorly understood and with limited structural information that could greatly aid in finding new drug candidates.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
Sanofi Q3 2014 Results - Interview with Jérôme Contamine
PR Newswire - Tue Oct 28, 2:00AM CDT
Sanofi, a global and diversified healthcare leader, reports results for the third-quarter of 2014. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on results and full year guidance.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
SmarTrend Watching for Potential Rebound in Shares of Banco Santander After 2.58% Loss
Comtex SmarTrend(R) - Mon Oct 27, 4:08PM CDT
Banco Santander (NYSE:SAN) traded in a range yesterday that spanned from a low of $8.51 to a high of $8.72. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $8.67 on volume of 38.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SAN: 8.27 (-0.10)
80% ECB Banks Pass Stress Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:55AM CDT
European banks emerged as healthier. Of 123 banks that were part of the stress test, only 24 failed to meet the minimum common equity ratio (CET1) level of 5.5%.
BCS: 14.91 (-0.10), SAN: 8.27 (-0.10), HSBC: 50.09 (-0.27), DB: 30.24 (-0.38), NBG: 2.34 (-0.09), RBS: 11.90 (-0.16), LYG: 4.82 (unch)
Review on Diversified Banks Stocks - US Bancorp, Banco Santander Brasil, Banco Santander, National Bank of Greece, and Comerica
PR Newswire - Fri Oct 24, 8:10AM CDT
Investor-Edge has initiated coverage on the following equities: US Bancorp (NYSE: USB), Banco Santander Brasil S.A. (NYSE: BSBR), Banco Santander S.A. (NYSE: SAN), National Bank of Greece S.A. (NYSE: NBG), and Comerica Inc. (NYSE: CMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 23, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,677.90, up 1.32% and the NASDAQ Composite closed at 4,452.79, up 1.60%. The S&P 500 finished the session 1.23% higher at 1,950.82. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Financials Sector Index ended the day at 308.34, up 0.98%, with the index advancing 4.62% on YTD basis. Register for your complimentary reports on these five stocks at:
SAN: 8.27 (-0.10), USB: 43.81 (-0.11), NBG: 2.34 (-0.09), CMA: 48.40 (-0.50), BSBR: 5.53 (-0.03)
Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
PR Newswire - Wed Oct 22, 9:54AM CDT
Santander Holdings USA, Inc. (SHUSA), parent company of Santander Bank, N.A., announced today that its Board of Directors declared a dividend on SHUSA's Preferred Stock. A dividend payment of $0.45625 per depositary share is payable on November 17, 2014 to holders of record on November 1, 2014 for SHUSA's Series C Non-Cumulative Perpetual Preferred Stock (NYSE: SOVPRC).
SAN: 8.27 (-0.10)
Results from Two Phase III Studies Added to U.S. Label of Genzyme's Aubagio
Business Wire - Mon Oct 20, 9:35AM CDT
Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio(R) (teriflunomide) in the product's U.S. label.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
Business Wire - Mon Oct 20, 7:01AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies' investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB(1), has been accepted for review by the U.S. Food and Drug Administration (FDA). If approved, it would be the first pediatric combination vaccine in the United States designed to help protect against six important diseases - diphtheria, tetanus, pertussis (whooping cough), polio (poliovirus types 1, 2, and 3), invasive disease caused by Haemophilus influenzae type b (Hib), and hepatitis B.
SAN: 8.27 (-0.10), MRK: 59.34 (+0.08), SNY: 45.69 (-0.17)
Regeneron Pharmaceuticals begins Phase 3 clinical study of dupilumab in adults patients with moderate-to-severe atopic dermatitis
M2 - Mon Oct 20, 6:53AM CDT
Biopharmaceutical company Regeneron Pharmaceuticals (NasdaqGS :REGN) said on Monday that it has dosed the first patients in a Phase 3 clinical study of dupilumab in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications in partnership with Sanofi (EURONEXT:SAN)(NYSE:SNY) .
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
PR Newswire - Mon Oct 20, 6:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Homeownership Programs, New Apps for Mortgage and Real Estate Professionals, Dividend, and Market Activity - Research Reports on Radian, Banco Santander, BioMed Realty, Chimera and Genworth
PR Newswire - Fri Oct 17, 7:35AM CDT
Today, Analysts Review released its research reports regarding Radian Group Inc. (NYSE: RDN), Banco Santander, S.A. (NYSE: SAN), BioMed Realty Trust Inc. (NYSE: BMR), Chimera Investment Corporation (NYSE: CIM) and Genworth Financial, Inc. (NYSE: GNW). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7255-100free.
SAN: 8.27 (-0.10), BMR: 21.44 (+0.02), RDN: 16.48 (+0.09), CIM: 3.14 (+0.01), GNW: 8.41 (-0.25)
Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
GlobeNewswire - Thu Oct 16, 7:19AM CDT
Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that it has entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN) and (NYSE:SNY).
IMDZ: 30.06 (-0.03), SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
New Survey Finds Differences In Attitudes About Diabetes Based On Age
PR Newswire - Wed Oct 15, 7:00AM CDT
Sanofi US announced today the findings of a new survey that reveals striking differences in opinion among various age groups about diabetes and available treatment options. In particular, the generation known as "millennials" (those aged 18 to 34) shows an uneasy mix of fear and ability to handle managing their diabetes, which is being diagnosed at a rate of 1.7 million new cases every year1.
SAN: 8.27 (-0.10), SNY: 45.69 (-0.17)
1 Bank Stock to Avoid at All Costs
Motley Fool Staff - Motley Fool - Mon Oct 13, 11:35AM CDT
There are certainly some bargains to be had in the banking sector, with many companies trading at historically low valuations and growing their operations very rapidly. However, some stocks might appear to be better investments than they actually...
SAN: 8.27 (-0.10), NYCB: 15.91 (+0.07), BAC: 17.36 (unch), FBP: 5.25 (unch), MCO: 98.95 (-0.04)
